Target intelligence / Profile preview

Carnitine palmitoyltransferase system (mainly Carnitine palmitoyltransferase 1 and 2) (CPT system (CPT1, CPT2))

Target
CPT system (CPT1, CPT2)
Molecular classification
Transporter, Enzyme
01

Overview

Fatty acid mitochondrial transport refers to the tightly regulated process by which long-chain fatty acids are transported from the cytosol into mitochondria, where they undergo β-oxidation to provide energy for the cell. This transport is mediated primarily by the carnitine palmitoyltransferase (CPT) system, which includes CPT1 on the outer mitochondrial membrane, carnitine-acylcarnitine translocase (CACT) in the inner membrane, and CPT2 on the inner mitochondrial membrane. These enzymes work together to shuttle fatty acyl-CoA derivatives across mitochondrial membranes by converting them to acylcarnitines, allowing passage, and then reconverting them back to fatty acyl-CoA inside the matrix. This process is essential in tissues with high-energy demands such as heart, skeletal muscle, and liver, and is regulated by nutritional status, hormonal signaling, and intracellular energy needs. Genetic disorders or pharmacologic inhibition of this pathway can lead to severe metabolic disturbances[2][3][1].

Other names
Carnitine shuttleCPT systemMitochondrial fatty acid importFatty acid β-oxidation entrance
02

Mechanism of action

Inhibition of carnitine palmitoyltransferase 1 reduces mitochondrial fatty acid uptake, lowering β-oxidation rates\nModulation of carnitine availability alters fatty acid flux into mitochondria

03

Biological functions

Cellular energy metabolismFatty acid oxidationLipid homeostasis
04

Disease associations

Metabolic diseasesCardiovascular diseaseLipotoxicityMitochondrial disease
05

Safety considerations

Hepatotoxicity (e.g., with etomoxir)Muscle weakness and hypoglycemia (with excessive inhibition)Disruption of energy metabolism, especially in high-energy–demand tissues
06

Interacting drugs

Etomoxir (CPT1 inhibitor)

2 more in the full profile.

07

Biomarkers

Plasma acylcarnitine levelsCPT1/2 expression levels in tissuesAccumulation of long-chain fatty acids in plasma (diagnosis of CPT deficiencies)

Beyond the preview

Go deeper on Carnitine palmitoyltransferase system (mainly Carnitine palmitoyltransferase 1 and 2) (CPT system (CPT1, CPT2)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carnitine palmitoyltransferase system (mainly Carnitine palmitoyltransferase 1 and 2) (CPT system (CPT1, CPT2)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call